Literature DB >> 24330161

Risk factors associated with preoperative fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae in liver transplant recipients.

F Bert1, B Larroque, F Dondero, F Durand, C Paugam-Burtz, J Belghiti, R Moreau, M-H Nicolas-Chanoine.   

Abstract

OBJECTIVE: The aim of the study was to identify risk factors associated with pre-transplant fecal carriage of extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae in liver transplant recipients. PATIENTS AND METHODS: Over a 3-year period (January 2009-December 2011), 317 patients who underwent liver transplantation were screened preoperatively for fecal carriage of ESBL-producing Enterobacteriaceae. Risk factors for fecal carriage were investigated by univariate analysis and stepwise logistic regression.
RESULTS: Of the 317 patients screened, 50 (15.7%) harbored an ESBL-producing isolate. Previous infection with an ESBL-producing organism had developed during the last 6 months in 20% of fecal carriers versus in none of the non-carriers. Other variables associated with fecal carriage were a model for end-stage liver disease score ≥25, pre-transplant stay in the intensive care unit ≥48 h, hospital stay ≥10 days in the last 6 months, a history of spontaneous bacterial peritonitis (SBP), exposure to a β-lactam agent in the last month, and prophylaxis with norfloxacin. Independent predictors of fecal carriage in the multivariate logistic regression model were exposure to a β-lactam agent in the month preceding transplantation (odds ratio [OR] = 7.8, confidence interval [CI] = 4-15.5, P < 0.001), and a history of SBP (OR = 2.4, CI = 1.1-4.9, P = 0.02).
CONCLUSIONS: Previous infection with an ESBL-producing isolate, recent exposure to a β-lactam agent, and a history of SBP are risk factors for preoperative fecal carriage of ESBL-producing Enterobacteriaceae in liver transplant recipients. Patients at risk of fecal carriage should receive intraoperative prophylaxis and, when necessary, empiric postoperative antimicrobial treatment that includes coverage for these organisms.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  ESBL; Enterobacteriaceae; extended-spectrum β-lactamase; fecal carriage; liver transplant; spontaneous bacterial peritonitis

Mesh:

Substances:

Year:  2013        PMID: 24330161     DOI: 10.1111/tid.12169

Source DB:  PubMed          Journal:  Transpl Infect Dis        ISSN: 1398-2273            Impact factor:   2.228


  9 in total

1.  High Heterogeneity of Multidrug-Resistant Enterobacteriaceae Fecal Levels in Hospitalized Patients Is Partially Driven by Intravenous β-Lactams.

Authors:  Eva M González-Barberá; Jaime Sanz; Ana Djukovic; Alejandro Artacho; Iván Peñaranda; Beatriz Herrera; María José Garzón; Miguel Salavert; José Luis López-Hontangas; Karina B Xavier; Bernhard Kuster; Laurent Debrauwer; Jean-Marc Rolain; Miguel A Sanz; Joao B Xavier; Carles Ubeda
Journal:  Antimicrob Agents Chemother       Date:  2020-01-27       Impact factor: 5.191

2.  Carbapenem-Resistant Enterobacteriaceae Acquired Before Liver Transplantation: Impact on Recipient Outcomes.

Authors:  Maristela Pinheiro Freire; Isabel C V S Oshiro; Ligia C Pierrotti; Patricia R Bonazzi; Larissa M de Oliveira; Alice T W Song; Carlos H Camargo; Inneke M van der Heijden; Flavia Rossi; Silvia F Costa; Luiz A C DʼAlbuquerque; Edson Abdala
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

3.  Infection prevention requirements for the medical care of immunosuppressed patients: recommendations of the Commission for Hospital Hygiene and Infection Prevention (KRINKO) at the Robert Koch Institute.

Authors: 
Journal:  GMS Hyg Infect Control       Date:  2022-04-13

4.  Simultaneous gut colonisation and infection by ESBL-producing Escherichia coli in hospitalised patients.

Authors:  Johny Asir; Shashikala Nair; Sheela Devi; Kenchappa Prashanth; Rajagopalan Saranathan; Reba Kanungo
Journal:  Australas Med J       Date:  2015-06-30

Review 5.  Management of bacterial and fungal infections in end stage liver disease and liver transplantation: Current options and future directions.

Authors:  Elda Righi
Journal:  World J Gastroenterol       Date:  2018-10-14       Impact factor: 5.742

6.  Infection Prevention in Transplantation.

Authors:  Steven A Pergam
Journal:  Curr Infect Dis Rep       Date:  2016-01       Impact factor: 3.725

7. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2021-02       Impact factor: 1.513

8.  Rates and causative pathogens of surgical site infections attributed to liver transplant procedures and other hepatic, biliary, or pancreatic procedures, 2015-2018.

Authors:  Nora Chea; Mathew R P Sapiano; Liang Zhou; Lauren Epstein; Alice Guh; Jonathan R Edwards; Katherine Allen-Bridson; Victoria Russo; Jennifer Watkins; Stephanie M Pouch; Shelley S Magill
Journal:  Transpl Infect Dis       Date:  2021-03-23

9.  High prevalence of multidrug-resistant gram-negative bacterial infection following pediatric liver transplantation.

Authors:  Chanita Phichaphop; Nopporn Apiwattanakul; Chonnamet Techasaensiri; Chatmanee Lertudomphonwanit; Suporn Treepongkaruna; Chollasak Thirapattaraphan; Sophida Boonsathorn
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.